Indonesia BPOM Tightens Mold准入 for Medical Silicone/Rubber Devices

On May 25, 2026, the Indonesian Food and Drug Authority (BPOM) updated its Technical Guidelines for Molds Used in Medical Device Manufacturing, introducing new compliance requirements for vulcanizing presses and associated molds used in the production of silicone- and rubber-based medical components—effective October 1, 2026.

New Regulatory Requirements for Medical Device Molds

BPOM revised the Technical Guidelines for Molds Used in Medical Device Manufacturing on May 25, 2026. Starting October 1, 2026, all vulcanizing presses and their配套 molds employed in manufacturing silicone or rubber parts for medical devices must hold both ISO 13485:2025 certification and an ISO 10993-5 cytotoxicity test report. Failure to meet these requirements will result in denial of registration and market authorization in Indonesia.

Impact Across the Medical Device Supply Chain

Exporters and Direct Trading Companies

These entities face heightened pre-market clearance risks: molds supplied to Indonesian manufacturers—whether as standalone tools or integrated into production lines—must now be verified for ISO 13485:2025 certification and ISO 10993-5 testing. Documentation gaps may delay product registration timelines or trigger re-submission requests.

Raw Material and Component Procurement Firms

Firms sourcing silicone/rubber compounds or mold-ready elastomers must ensure downstream compatibility with certified tooling. Suppliers may need to adjust material specifications or provide additional biocompatibility data to align with mold-level validation expectations.

Contract Manufacturers and OEMs

Manufacturers operating in or exporting to Indonesia must reassess their mold qualification protocols. Existing vulcanizing equipment and molds—especially those previously qualified under older standards—require re-evaluation, recertification, or replacement before October 2026 to maintain regulatory continuity.

Supply Chain Support Providers

Logistics, certification support, and regulatory consulting firms must update service offerings to include ISO 13485:2025 gap assessments and ISO 10993-5 test coordination—particularly for molds intended for direct contact with medical-grade elastomers.

Key Compliance Actions for Enterprises

Verify ISO 13485:2025 Certification Scope

Confirm that the certificate explicitly covers mold design, fabrication, and maintenance activities—not only device manufacturing—and is issued by a BPOM-recognized certification body.

Secure Valid ISO 10993-5 Cytotoxicity Reports

Reports must be generated using the actual mold surface materials (e.g., steel grade, coating, release agents) and reflect real-world processing conditions—including vulcanization temperature, pressure, and cycle duration.

Align Technical Documentation with BPOM’s Registration Workflow

Mold-related technical files—including design history, risk analysis (ISO 14971), and traceability records—must be structured to support BPOM’s registration dossier requirements, especially for Class B and higher-risk devices.

Review Supplier Qualification Protocols

Enterprises must extend audit criteria to include mold suppliers’ quality management systems and biocompatibility test validity—moving beyond traditional dimensional or mechanical performance checks.

Industry Observation: Beyond Tooling, a Systemic Shift

Analysis shows this amendment reflects BPOM’s broader move toward upstream risk control: rather than focusing solely on finished devices, regulators are now holding critical production enablers—like molds—to equivalent biocompatibility and quality system standards. It is more appropriate to understand this as a de facto extension of the medical device quality system to tooling infrastructure. What deserves closer attention is the implied lead time: full ISO 13485:2025 implementation typically requires 6–12 months, and ISO 10993-5 testing adds further validation cycles—making early readiness essential for uninterrupted supply.

Strategic Implication for Market Access

This requirement signals a maturing regulatory posture in Indonesia—one that treats production tooling not as generic industrial equipment, but as integral, patient-impacting elements of the medical device lifecycle. While not unprecedented globally, its enforcement timing and scope present a distinct operational inflection point for exporters and local manufacturers alike. Proactive alignment—not reactive compliance—will define competitive advantage in the coming 12 months.

Source Attribution and Monitoring Notes

This article is based exclusively on the provided title, event date (May 25, 2026), and summary description. Specific official source links were not provided in the input and should be verified continuously. Stakeholders are advised to monitor BPOM’s official announcements for implementation guidance, interpretation clarifications, certification body recognition updates, and potential transitional arrangements ahead of the October 1, 2026 deadline.